Scientific Research
ABK Biomedical Scientific Research
ABK Biomedical is committed to improving every aspect of Y90 radioembolization treatment and patient follow-up.
We are dedicated to improving patient outcomes; from engineering microsphere technology and delivery systems for optimal imaging and tumor targeting to ensuring physicians know the cutting-edge advantages of Eye90 microspheres Precision Dosimetry™.
Eye90 microspheres Precision Dosimetry™
Precision Dosimetry involves a CT-based approach to calculating the post-treatment absorbed dose. The benefits of Precision Dosimetry include significantly enhanced spatial resolution of the dose distribution and a more accurate estimation of dose heterogeneity.
Current Y90 microsphere technology lacks sufficient radiopacity for CT-based dosimetry to be feasible.
Eye90 microspheres™ are engineered to be radiopaque, permitting Precision Dosimetry with CT-based imaging to be utilized. The clinical potential of Eye90 microspheres Precision Dosimetry™ has been demonstrated in a pre-clinical model and published in a well-respected peer-reviewed journal.

Eye90 microspheres Precision Dosimetry™ in a rabbit model. a–c Axial, sagittal, and coronal views of CT-based dose distribution. d–f Axial, sagittal, and coronal views of traditional PET-based dose distribution showing inferior resolution.
Scientific Presentations
Read the abstract!
CT-based Dosimetry in Yttrium-90 Radioembolization Performed in a Rabbit Liver Model. Dr E. Courtney Henry, Dalhousie University
Global Embolization Symposium and Technologies Annual Meeting 2021
- The poor spatial resolution encountered with Y90 PET and SPECT dosimetry underestimates the true dose heterogeneity following radioembolization.
- Improved estimates of distribution can be obtained with higher resolution dosimetry to accurately quantify dose-response and identify areas at risk of recurrence.
- The steep dose gradients observed with CT-based dosimetry are highly correlated with radioembolized vasculature because it is directly derived from the microspheres implanted distribution.
- The strong positive correlation between radiopaque microspheres and CT-based dosimetry may help physicians with dose-response relationships and improve future patient outcomes.
Read the abstract!
Novel Hepatic Tumor Microvascular Model for Evaluating the Microembolic Characteristics of Y-90 Microspheres. Dr. Sam Miller, NC State University.
Global Embolization Symposium and Technologies Annual Meeting 2021
- Attributes of Y90 distribution in tumors are difficult to observe through in vivo models. This is the first published in vitro model simulating HCC tumors down to the arteriole level (18µm).
- This study compared in vitro microsphere distribution between the ABK dual-syringe delivery system (DS) a typical glass Y90 bolus delivery system (BD).
- The use of the ABK DS system resulted in greater a greater number of microspheres penetrating distally compared to BD.
- A more uniform distribution of microspheres was also observed with ABK DS vs BD.
- This study demonstrated that the mode of microsphere delivery affects penetration and uniformity of deposition, and may bring a new perspective to Y90 technology development.
Peer-Reviewed Publications
Precision dosimetry in yttrium‑90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model
Henry et al. EJNMMI Physics (2022) 9:21
Click to download the article
Quantification of the inherent radiopacity of glass microspheres for precision dosimetry in yttrium-90 radioembolization.
Henry et al 2019 Biomed. Phys. Eng. Express 5 055011
Click to read this abstract
Post-administration dosimetry in yttrium-90 radioembolization through micro-CT imaging of radiopaque microspheres in a porcine renal model
Henry et al 2021 Phys. Med. Biol. 66 095011
Click to read this abstract
ABK's Business Partners
ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.
Investment Partners
Research Partners
Development Partners
The ABK Biomedical Team
We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.
ABK Biomedical is an equal opportunity employer offering competitive compensation packages.
Corporate Offices
Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada
T. 902.442.4009
Orange County Office
555 Corporate Drive
Suite 105
Ladera Ranch, CA, 92694
USA
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. ABK Biomedical Inc. products are considered investigational products and are NOT FDA approved for use. Y90 radioembolization
Copyright 2022 - All International Rights Reserved